AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00217100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet a day
Study NCT01871285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study NCT01871285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo film
Description: Matching placebo buccal film
Study NCT01871285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
Study NCT01871285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
Study NCT03837756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefitolimod
Description: A TLR9 agonist administered s.c. once weekly for 8 weeks.
Study NCT03837756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3BNC117 and 10-1074
Description: Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
Study NCT03746574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Curriculum
Description: 12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
Study NCT01871285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427 600 mg
Description: Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427 1000 mg
Description: Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study NCT02276547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Description: Transcatheter mitral valve replacement
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients will receive gemcitabine (1000 mg/m\^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study NCT01454089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m\^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
Study NCT02093975 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPad air with 4G/3G SIM card
Description: iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation
Study NCT02093975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad air with 4G/3G SIM card
Description: iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation
Study NCT01095952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVNS ON
Description: Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
Study NCT00745264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 100 mg Ketoprofen to 2 joints
Study NCT00745264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 400 mg ketoprofen to 4 joints
Study NCT00745264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 100 and 400 mg Ketoprofen used concomittant with heat
Study NCT00745264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diractin
Description: 100 and 400 mg Ketoprofen concomittant with moderate exercise
Study NCT01765764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost solution
Description: Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
Study NCT01765764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle to bimatoprost solution
Description: Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
Study NCT01765764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle to bimatoprost solution
Description: Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
Study NCT00233220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent, multi-level intervention targeted at physicians and patients
Description: The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
Study NCT00233220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive usual care.
Study NCT03786705 — intervention group
Intervention type: OTHER
Intervention: Massive transfusion
Description: Trauma patients who had received blood transfusion≥10 U
Study NCT03786705 — intervention group
Intervention type: OTHER
Intervention: Non-Massive Transfusion
Description: Trauma patients who had received blood transfusion\<10 U
Study NCT02560051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
Study NCT00169741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Renogram
Description: Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
Study NCT02560051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
Study NCT02560051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
Study NCT02560051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estramustine
Description: In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
Study NCT02560051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
Study NCT02041013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking Card
Description: Recordable greeting card-style discharge instruction card
Study NCT02538549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACE4
Description: Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
Study NCT04135261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM4003
Description: Intravenous (IV) administration
Study NCT04657315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MSC11FCD
Description: Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10\^7, 3x10\^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery.~Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day~Directions:~Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery.~Route of administration: Oral administration
Study NCT00400634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Description: CERE-120 5.4 x 10\^11 vg
Study NCT00400634 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Description: Bilateral partial thickness burr holes placed, no intraparenchymal injections
Study NCT01598896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol titrated to 5 mg three times daily
Study NCT04349761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MyMD1
Description: Isomyosamine 5mg capsules
Study NCT01598896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 0.1 mg twice daily
Study NCT01598896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule by mouth twice daily
Study NCT02517424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/Low CBD Cannabis
Description: Dried cannabis
Study NCT02517424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High THC/High CBD Cannabis
Description: Dried cannabis
Study NCT02517424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low THC/Low CBD Cannabis
Description: Dried cannabis
Study NCT01401296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
Study NCT01401296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: Behavioral: the wait-list group receives Deprexis after 8 weeks
Study NCT03612973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lipid profile
Description: Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
Study NCT03612973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fasting insulin
Description: serum samples used for doing the test by ELISA after fasting for 8 h
Study NCT03612973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibro scan
Description: liver stiffness by fibro scan before and after treatment
Study NCT03215888 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
Study NCT04661553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mueller's polarimetric colposcopy Group 2
Description: Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population at high-risk of preterm birth.~This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for an abnormal pregnancy and, therefore, to predict premature childbirth.
Study NCT01384643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
Study NCT02971696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
Study NCT01276496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Given IV
Study NCT01276496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01276496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01276496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03336788 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS - ) MagPro®
Description: 20 sessions navigated with Conventional Transcranial Magnetic Stimulation
Study NCT02971696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive care
Description: Liver Support, pain management
Study NCT02625142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered rounds checklist tool
Description: A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
Study NCT03907631 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: care decisions driven by local physicians; this is an observational cohort
Study NCT01384643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
Study NCT02351986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: A 20 minutes ice pack cryotherapy applied for 4 consecutive days
Study NCT02351986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice pack
Study NCT03961373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with D2 lymphadenectomy
Description: Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
Study NCT03961373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy with D2plus lymphadenectomy
Description: Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
Study NCT01095471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
Study NCT02992080 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: miRNAs isolation from blood samples of patients and control
Description: Blood sample collection in specific PAXGene tubes
Study NCT04608942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jett Plasma Medical Lift
Description: Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
Study NCT04608942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Debridement
Description: Plasma Application versus Mechanical Debridement in refractory meibomian gland dysfunction
Study NCT00566501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil SR 23 mg once daily orally.
Study NCT02660398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardized NMBD Management
Description: The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
Study NCT01227148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tightly glucose control
Description: A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
Study NCT01227148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional glucose control
Description: a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
Study NCT04079569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.